Mushroom Supplement Dosage Crisis: 3 Alarms for Extract Suppliers
Let me state the overall judgment first: on the surface, this review criticizes “non-standard reporting in human trials,” but what it really strikes at is the most commonly used logic in supplement marketing – “the literature says it works, so my product works too.” The single sentence “they reported how much was taken, but not what material was actually tested” happens to break this endorsement chain right in the middle. For people who make plant extracts and supply B2B raw materials, this deserves more careful reading than any efficacy claim.

1. The Fact That a “Guide” Was Rewritten into a “Deficiency Report” Is Itself a Signal
What Robin Gurney originally wanted to do was create a “recommended dosage guide for functional mushrooms.” But after reviewing the literature, he found that the evidence could not support such a guide, so he simply changed direction and wrote a review reporting the deficiencies. This fact itself is more telling than the content of the review: a B2B supplier who deals with raw materials every day, after doing a large amount of research, did not conclude “how many grams people should take,” but instead concluded “people have not even clearly reported what they are actually eating.” This shows that the problem has become serious enough to push an insider to give up organizing information and turn to exposure instead. The paper was posted on the open preprint platform Zenodo and was accepted as a poster by the IMMC13 International Medicinal Mushroom Conference, which shows that this is not personal grumbling, but the publicization of a consensus within the industry.
2. The Critical Point: Dosage Numbers “Look Accurate, but Are Actually Empty”
Numbers like “3 grams a day” and “500 milligrams a day” can be seen everywhere in papers and in brand marketing, and readers naturally assume that they are comparable and reproducible. What Gurney points out is the fracture in this chain of trust: behind the milligram number, what is actually inside can be completely different – fruiting body powder, concentrated extract, blended formulation, spore product, or a formula with added carriers. Breaking it down further, fungal part, strain, cultivation conditions, harvest maturity, post-harvest treatment, extraction route, carrier content, batch-to-batch consistency and chemical profile – if any one of these nine variables is different, “the same gram number” means two completely different products.
For the plant extract industry, the destructive power of this sentence lies in the fact that the conclusions of efficacy studies are bound to “that specific batch of material,” not to “this mushroom.” To use literature as an endorsement for a product, one must first answer the question “whether my material is comparable to the material in the literature.” The sentence that Gurney suggested brands should ask their suppliers – “Is your material really comparable to the material used in that study in the literature?” – will change in the future from a soul-searching question into a standard purchasing action.
3. The Eight-Item Reporting Framework Is Essentially Defining “Comparability”
The eight reporting requirements proposed in the paper – (1) fungal part, (2) species identity and identification, (3) cultivation substrate and conditions, (4) harvest maturity and post-harvest treatment, (5) extraction and processing, (6) carriers and excipients, (7) batch identity, consistency and compositional integrity, and (8) target compounds or metabolite profile – are on the surface a checklist for academic papers, but in fact they are the specification of a “raw material identity data card.” It breaks down “what this mushroom is” into eight verifiable dimensions; if any one dimension is missing, the data are incomplete.
This list has direct value for people who make raw materials: it announces in advance what buyers’ future acceptance standards will be. When the academic world pushes the eight-item reporting, brands will sooner or later review suppliers with the same framework – at that time, whoever first prepares complete data according to these dimensions will pass the review; whoever cannot provide them will be left in the old world.
4. The Nammex Case: The Problem Is No Longer Just “Incomplete Reporting,” but “Fake Products on the Market”
The reactions of insiders show that this is not empty talk. Nammex’s study comparing commercially available Chaga (Int. J. Mol. Sci. 2025) found that several samples “are basically fermented grain substrates” – with very low levels of characteristic triterpenes and phenolics and very high starch content. Chioffi’s exact words deserve to be read again and again: “This is not a small label flaw; the product simply does not contain what the studies say it should have.” Translated into industry language, this means: the disorder in the market is no longer just “the formula is not clearly written,” but structural adulteration or substitution exists, and ordinary consumers, or even most downstream brands, have no ability to detect it.
The addition of Stefan Gafner, chief science officer of the American Botanical Council, also adds another dimension to the problem: solid chemical characterization should have been part of human trials, yet many papers still fail to do it today; reishi is an even worse disaster zone – with confusing naming and unclear taxonomic status. Note this detail: reishi is one of the most popular mushrooms on the market, with the most research and the most product claims, and it is exactly the one that is the most chaotic. This confirms a rule: the hotter a raw material is, the easier it is for the commercial side to turn its “scientific identity” into a complete mess, because the participants are a mix of the good and the bad, and the interests involved are the largest.
5. The Comparison Between Lion’s Mane and Reishi Shows the “Degree of Disorder”
The review mentions that lion’s mane dosages based on fruiting bodies are relatively concentrated (around 2.0-3.2 g/day in several places), while reishi covers a wide range and is extremely heterogeneous. The meaning of this comparison is not in the dosages themselves, but in the fact that even when examined under the same eight-item framework, different raw materials have different levels of disorder. The more heterogeneous a raw material is, the more it is “the same kind but a different thing,” and the more it needs a chemical profile to anchor its identity.
What People in the Plant Extract Business Should Take Away:
First, “evidence of comparability” is the hard currency of the next round of B2B trust. Brands will become more and more serious about “whether your material is the same thing as the material in the literature.” Whoever can proactively provide chemical profiles, marker compound contents and batch-to-batch consistency data will get orders first, instead of waiting to be asked.
Second, turn the eight-item framework directly into product data cards. Species identification, source part, cultivation and harvest conditions, extraction process, carriers, batch number and chemical profile – preparing raw material files according to these dimensions is essentially turning the review’s requirements into your own sales materials in advance. This applies to mushroom raw materials, and the same logic applies to natural extracts like white orchid concrete (Michelia alba): a clear chemical profile, stable batches and traceable sources are exactly the reasons to raise prices and lock in customers.
Third, a period of chaos is exactly a period of branding. When the reishi market is full of “fermented grain pretending to be Chaga,” confusing naming and missing chemical characterization, a supplier with transparent data does not need to advertise – the standards themselves will filter out competitors. When the tide goes out, those who take chemical characterization seriously will stay, and those who just go through the motions will be eliminated.
The true value of this review for the plant extract industry: it has turned “whether what we sell is the thing the literature talks about” from a marketing question into a scientific and compliance question – and for those who cannot answer it now, they will be asked sooner or later.





